ADC ID	DRG0PWAOJ
ADC Name	SGN-CD228A
Synonyms	SGN CD228A; anti-CD228 antibody-drug conjugate; Anti-CD228-MMAE    Click to Show/Hide
Organization	Seagen Inc.
Drug Status	Phase 1
Indication	In total 6 Indication(s) Breast cancer [ICD11:2C60-2C65] Phase 1 Colorectal cancer [ICD11:2B91] Phase 1 Melanoma [ICD11:2C30] Phase 1 Non-small cell lung cancer [ICD11:2C25] Phase 1 Pancreatic cancer [ICD11:2C10] Phase 1 Pleural mesothelioma [ICD11:2C26] Phase 1
Drug-to-Antibody Ratio	8
	3D MOL			2D MOL
Antibody Name	Humanized Anti-CD228 SGN-CD228A mAb					Antibody Info
Antigen Name	Melanotransferrin (MELTF)					Antigen Info
Payload Name	Monomethyl auristatin E					Payload Info
Therapeutic Target	Microtubule (MT)					Target Info
Linker Name	Beta-Glucuronidase cleavable linker					Linker Info
DrugMap ID	DMSVD2R
TTD ID	DS6BE2

Standard Type	NCT Number	Clinical Status	Clinical Trial Description
Undisclosed	NCT04042480	Phase 1	A phase 1 study of SGN-CD228A in select advanced solid tumors.

Standard Type	Value	Units	Animal Model (No. of PDX)
Tumor Growth Inhibition value (TGI)	75	%	NSCLC PDX model
Tumor Growth Inhibition value (TGI)	100	%	NSCLC PDX model

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	50	%	SK-MEL-5 cells	Cutaneous melanoma
Tumor Growth Inhibition value (TGI)	62.5	%	COLO 853 cells	Cutaneous melanoma
Tumor Growth Inhibition value (TGI)	100	%	Calu-1 cells	Lung squamous cell carcinoma

Experiment 1 Reporting the Activity Date of This ADC					[1]
Related Clinical Trial
NCT Number	NCT04042480	Clinical Status	Phase 1
Clinical Description	A phase 1 study of SGN-CD228A in select advanced solid tumors.

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	75.00%	Positive CD228 expression (CD228+++/++)
Method Description	SGN-CD228A was evaluated for antitumor activity in melanoma and NSCLC xenograft and PDX models.SGN-CD228A was administered at a single dose of 3.00 mg/kg.
In Vivo Model	NSCLC PDX model
Experiment 2 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	100.00%	Positive CD228 expression (CD228+++/++)
Method Description	SGN-CD228A was evaluated for antitumor activity in melanoma and NSCLC xenograft and PDX models.SGN-CD228A was administered at a single dose of 1.00 mg/kg.
In Vivo Model	NSCLC PDX model

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	50.00%	Positive CD228 expression (CD228+++/++)
Method Description	SGN-CD228A was evaluated for antitumor activity in melanoma and NSCLC xenograft and PDX models.SGN-CD228A was administered at a single dose of 1.00 mg/kg.
In Vivo Model	Melanoma CDX model
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 2 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	62.50%	Positive CD228 expression (CD228+++/++)
Method Description	SGN-CD228A was evaluated for antitumor activity in melanoma and NSCLC xenograft and PDX models.SGN-CD228A was administered at a single dose of 1.00 mg/kg.
In Vivo Model	Melanoma CDX model
In Vitro Model	Cutaneous melanoma	COLO 853 cells		CVCL_2003
Experiment 3 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	100.00%	Positive CD228 expression (CD228+++/++)
Method Description	SGN-CD228A was evaluated for antitumor activity in melanoma and NSCLC xenograft and PDX models.SGN-CD228A was administered at a single dose of 1.00 mg/kg.
In Vivo Model	Squamous NSCLC CDX model
In Vitro Model	Lung squamous cell carcinoma	Calu-1 cells		CVCL_0608

Ref 1	A Phase 1 Study of SGN-CD228A in Select Advanced Solid Tumors
Ref 2	SGN-CD228A: A novel humanized anti-CD228 antibody-drug conjugate for the treatment of solid tumors.